Biomarkers of the extracellular matrix and of collagen fragments

Clinica Chimica Acta

Volumn 443, Issue , 2015, Pages 39-47

  Chalikias, Georgios K ^a   Tziakas, Dimitrios N ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Biomarker; Collagen; Extracellular matrix; Heart failure; Peptides

Indexed keywords

AMINO TERMINAL PROPEPTIDE COLLAGEN TYPE 1; BIOLOGICAL MARKER; CARBOXY TERMINAL PROPEPTIDE COLLAGEN TYPE 1; CARBOXY TERMINAL PROPEPTIDE COLLAGEN TYPE 3; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SCLEROPROTEIN; UNCLASSIFIED DRUG; COLLAGEN TYPE 2;

ARTICLE; CARDIOVASCULAR DISEASE; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; COMORBIDITY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFECT; EXTRACELLULAR MATRIX; HUMAN; LABORATORY TEST; NONHUMAN; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; BLOOD; HEART FAILURE; METABOLISM; PATHOLOGY;

BIOMARKERS; COLLAGEN TYPE I; COLLAGEN TYPE II; EXTRACELLULAR MATRIX; HEART FAILURE; HUMANS;

EID: 84924236279     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.06.028     Document Type: Article

References (112)

1. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989, 13:1637-1652.
2. Lopez B., Conzalez A., Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010, 120:1645-1654.
3. Bowers S.L.K., Banerjee I., Baudino T.A. The extracellular matrix: at the center of it all. J Mol Cell Cardiol 2010, 48:474-482.
4. Laurent G.J. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987, 252(pt 1):C1-C9.
5. Schelbert E.B., Fonarrow G.C., Bonow R.O., Butler J., Gheorghiades M. Therapeutic targets in heart failure: refocusing on the myocardial interstitium. J Am Coll Cardiol 2014, 10.1016/j.jacc.2014.01.068.
6. Shirani J., Dilsizian V. Imaging left ventricular remodeling: targeting the neurohumoral axis. Nat Clin Pract Cardiovasc Med 2008, 5(Suppl. 2):S57-S62.
7. Weber K.T. Monitoring tissue repair and fibrosis from a distance. Circulation 1997, 96:2488-2492.
8. De Jong S., Van Veen T.A.B., De Bakker J.M.T., Vos M.A., Van Rijen H.V.M. Biomarkers of myocardial fibrosis. J Cardiovasc Pharmacol 2011, 57:522-535.
9. Medugorac I., Jacob R. Characterisation of left ventricular collagen in the rat. Cardiovasc Res 1983, 17:15-21.
10. Bishop J.E., Laurent G.J. Collagen turnover and its regulation in the normal and hypertrophying heart. Eur Heart J 1995, 16(Suppl.C):38-44.
11. Zannad F., Rossignol P., Iraqi W. Extracellular matrix fibrotic markers in heart failure. Heart Fail Rev 2010, 15:319-329.
12. Brower G.L., Gardner J.D., Forman M.F., et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006, 30:604-610.
13. Eghbali M., Weber K.T. Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. Mol Cell Biochem 1990, 96:1-14.
14. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210.
15. Lopez B., Gonzalez A., Varo N., Laviades C., Querejeta R., Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001, 38:1222-1226.
16. Risteli J., Risteli L. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol 1995, 22(Suppl.):77-81.
17. Risteli L., Risteli J. Non-Invasive Methods for Detection of Organ Fibrosis 1990, CRC Press, Boca Raton, FL.
18. Jensen L.T., Host N.B. Collagen: scaffold for repair or execution. Cardiovasc Res 1997, 33:535-539.
19. Trackman P.C. Diverse biological functions of extracellular collagen processing enzymes. J Cell Biochem 2005, 96:927-937.
20. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006, 11:1696-1701.
21. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993, 39:635-640.
22. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
23. Maquart F.X., Pickart L., Laurent M., Gillary P., Momboisse J.C., Borel J.P. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide copper complex glycyl-L-histidyl-L-lysine-Cu2. FEBS Lett 1988, 238:343-346.
24. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
25. Gonzalez A., Lopez B., Ravassa S., et al. Biochemical markers of myocardial remodeling in hypertensive heart disease. Cardiovasc Res 2009, 81:509-518.
26. Querejeta R., Lopez B., Gonzalez A., et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004, 110:1263-1268.
27. Lopez B., Querejeta R., Gonzalez A., Sanchez E., Larman M., Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004, 43:2028-2035.
28. Izawa H., Murohara T., Nagata K., et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005, 112:2940-2945.
29. Lijnen P.J., Maharani T., Finahari N., Prihadi J.S. Serum collagen markers and heart failure. Cardiovasc Hematol Disord Drug Target 2012, 12:51-55.
30. Alla F., Kearney-Schwartz A., Radauceanu A., Das Dores S., Dousset B., Zannad F. Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur J Heart Fail 2006, 8:147-153.
31. Plaksej R., Kosmala W., Frantz S., et al. Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. J Hypertens 2009, 27:2483-2491.
32. Schwartzkopff B., Fassbach M., Pelzer B., Brehm M., Strauer B.E. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 2002, 4:439.
33. Lombardi R., Betocchi S., Losi M.A., et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 2003, 108:1455-1460.
34. Gonzalez A., Lopez B., Querejeta R., Zubillaga E., Echeverría T., Díez J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010, 55:1418-1424.
35. Querejeta R., Varo N., Lopez B., et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000, 101:1729-1735.
36. Diez J., Querejeta R., Lopez B., Gonzalez A., Larman M., Ubago M.J.L. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002, 105:2512-2517.
37. Martos R., Baugh J., Ledwidge M., et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007, 115:888-895.
38. Barasch E., Gottdiener J.S., Aurigemma G., et al. Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study. Circ Heart Fail 2009, 2:303-310.
39. Ho C.Y., Lopez B., Coelho-Filho O.R., et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010, 363:552-563.
40. Müller-Brunotte R., Kahan T., Lopez B., et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens 2007, 25:1958-1966.
41. Jimenez-Navarro M.F., Gomez-Doblas J.J., Cabrera-Bueno F., et al. Collagen synthesis and heart failure. Rev Esp Cardiol 2005, 58:975-978.
42. Risteli J., Risteli L. Collagen Metabolites in Body Fluids 2002, Wiley-Liss, New York, NY.
43. Kaye D.M., Khammy O., Mariani J., Maeder M.T. Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure. Eur J Heart Fail 2013, 15:292-298.
44. Phelan D., Watson C., Martos R., et al. Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes. PLoS One 2012, 7:e49259. 10.1371/journal.pone.0049259.
45. Lin Y.H., Lin L.Y., Wu Y.W., et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009, 409:96-99.
46. Chatzikyriakou S.V., Tziakas D.N., Chalikias G.K., et al. Resolution of symptoms and serum peptides of collagen type I turnover in acute heart failure patients. Acta Cardiol 2009, 64:29-33.
47. Klappacher G., Franzen P., Haab D., et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995, 75:913-918.
48. Diez J., Laviades C., Mayor G., Gil M.J., Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation 1995, 91:1450-1456.
49. Rossi A., Cicoira M., Golia G., et al. Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis. Heart 2004, 90:650-654.
50. Biolo A., Rohde L.E., Goldraich L.A., Mascarenhas M., Palombini D.V., Clausell N. Serum procollagen type III is associated with elevated right-sided filling pressures in stable outpatients with congestive heart failure. Biomarkers 2009, 14:438-442.
51. Wang T.J., Larson M.G., Benjamin E.J., et al. Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community. Am Heart J 2007, 154:291-297.
52. Zile M.R., DeSantis S.M., Baica C.F., et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011, 4:246-256.
53. Shah N.R., Bieniarz M.C., Basra S.S., et al. Serum biomarkers in severe refractory cardiogenic shock. JACC Heart Fail 2013, 1:200-206.
54. Bishu K., Deswal A., Chen H.H., et al. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J 2012, 164:763-770.
55. de Denus S., Lavoie J., Ducharme A., et al. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction. Can J Cardiol 2012, 28:62-68.
56. Collier P., Watson C.J., Voon V., et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?. Eur J Heart Fail 2011, 13:1087-1095.
57. Biolo A., Fisch M., Balog J., et al. Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Circ Heart Fail 2010, 3:44-50.
58. Poulsen S.H., Høst N.B., Jensen S.E., Egstrup K. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 2000, 101:1527-1532.
59. Sato Y., Kataoka K., Matsumori A., et al. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart 1997, 78:505-508.
60. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix. When is enough enough?. Circulation 2003, 108:1395-1403.
61. Yamamoto K., Masuyama T., Sakata Y., et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002, 55:76-82.
62. Diez J., Panizo A., Gil M.J., Monreal I., Hernandez M., Pardo Mindan J. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation 1996, 93:1026-1032.
63. Cicoira M., Rossi A., Bonapace S., et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 2004, 10:403-411.
64. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
65. Krum H., Elsik M., Schneider H.G., et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail 2011, 4:561-568.
66. Blangy H., Sadoul N., Dousset B., et al. Serum BNP, HS-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace 2007, 9:724-729.
67. Kitahara T., Takeishi Y., Arimoto T., et al. Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Circ J 2007, 71:929-935.
68. Kanoupakis E.M., Manios E.G., Kallergis E.M., et al. Serum markers of collagen turnover predict future shocks in implantable cardioverter defibrillator recipients with dilated cardiomyopathy on optimal treatment. J Am Coll Cardiol 2010, 55:2753-2759.
69. Manhenke C., Orn S., Squire I., et al. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int J Cardiol 2011, 150:277-282.
70. Eschalier R., Fertin M., Fay R., et al. Extracellular matrix turnover biomarkers predict long-term left ventricular remodeling after myocardial infarction: insights from the REVE-2 study. Circ Heart Fail 2013, 6:1199-1205.
71. Agrinier N., Thilly N., Boivin J.M., Dousset B., Alla F., Zannad F. Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a community-based prospective cohort study. Fundam Clin Pharmacol 2013, 27:572-580.
72. Lopez-Andres N., Rossignol P., Iraqi W., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012, 14:74-81.
73. Ho Y.L., Lin Y.H., Lee C.M., et al. Prognostic significance of adipocytokines and extracellular matrix activity in heart failure patients with high B-type natriuretic peptide. Clin Biochem 2009, 42:1407-1412.
74. Radauceanu A., Ducki C., Virion J.M., et al. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail 2008, 14:467-474.
75. Tziakas D.N., Chalikias G.K., Stakos D., et al. Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. Eur J Prev Cardiol 2012, 19:62-71.
76. Barthélémy O., Beygui F., Vicaut E., et al. OPERA Investigators. Relation of high concentrations of plasma carboxy-terminal telopeptide of collagen type I with outcome in acute myocardial infarction. Am J Cardiol 2009, 104:904-909.
77. Chatzikyriakou S.V., Tziakas D.N., Chalikias G.K., et al. Circulating levels of a biomarker of collagen metabolism are associated with health-related quality of life in patients with chronic heart failure. Qual Life Res 2012, 21:143-153.
78. Hutchinson K.R., Guggilam A., Cismowski M.J., et al. Temporal pattern of left ventricular structural and functional remodeling following reversal of volume overload heart failure. J Appl Physiol 2011, 111:1778-1788.
79. Manhenke C., Ueland T., Jugdutt B.I., et al. The relationship between markers of extracellular cardiac matrix turnover: infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI. Eur Heart J 2014, 35:395-402.
80. Chatzikyriakou S.V., Tziakas D.N., Chalikias G.K., et al. Chronic heart failure patients with high collagen type I degradation marker levels benefit more with ACE-inhibitor therapy. Eur J Pharmacol 2010, 628:164-170.
81. Kampourides N., Tziakas D., Chalikias G., et al. Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone. Am J Cardiol 2012, 110:1085-1091.
82. Zannad F., Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail Rev 2005, 10:71-78.
83. Lopez B., Gonzalez A., Querejeta R., Diez J. The use of collagen- derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 2005, 23:1445-1451.
84. Ciulla M.M., Paliotti R., Esposito A., et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis : results of a randomized trial. Circulation 2004, 110:552-557.
85. Sasamura H., Kitamura Y., Nakamura M., Ryuzaki M., Saruta T. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension. Clin Exp Hypertens. 2006, 28:511-520.
86. Deswal A., Richardson P., Bozkurt B., Mann D.L. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 2011, 17:634-642.
87. Udelson J.E., Feldman A.M., Greenberg B., et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail 2010, 3:347-353.
88. Iraqi W., Rossignol P., Angioi M., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009, 119:2471-2479.
89. Li M.J., Huang C.X., Okello E., Yanhong T., Mohamed S. Treatment with spironolactone for 24weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. Can J Cardiol 2009, 25:523-526.
90. Mak G.J., Ledwidge M.T., Watson C.J., et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009, 54:1674-1682.
91. Anguita M., Castro Beiras A., Cobo E., et al. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. TORAFIC Investigators Group. Clin Ther 2011, 33:1204-1213.
92. Umar S., Bax J.J., Klok M., et al. Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy. Eur J Heart Fail 2008, 10:878-883.
93. Marín F., Roldán V., Martinez J.G., et al. Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic state and tissue remodeling in systolic heart failure: a pilot study. Thromb Res 2011, 128:391-394.
94. Dong Y.X., Burnett J.C., Chen H.H., et al. Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure. J Interv Card Electrophysiol 2011, 30:241-249.
95. Wu C., Kato T.S., Pronschinske K., et al. Dynamics of bone turnover markers in patients with heart failure and following haemodynamic improvement through ventricular assist device implantation. Eur J Heart Fail 2012, 14:1356-1365.
96. ten Brinke E.A., Witkowski T.G., Delgado V., et al. Myocardial collagen turnover after surgical ventricular restoration in heart failure patients. Eur J Heart Fail 2011, 13:1202-1210.
97. Chubb S.A.P. Measurement of C-terminal telopeptide of type I collagen (CTX) in serum. Clin Biochem 2012, 45:928-935.
98. Risteli J., Risteli L. Assays of type I procollagen domains and collagen fragments: problems to be solved and future trends. Scand J Clin Lab Invest Suppl 1997, 227:105-113.
99. Lopez B., Querejeta R., Gonzalez A., Larman M., Diez J. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension 2012, 60:677-683.
100. Janicki J.S., Brower G.L. The role of myocardial fibrillar collagen in ventricular remodeling and function. J Card Fail 2002, 8(Suppl.):S319-S325.
101. Lopez B., Gonzalez A., Querejeta R., Larman M., Diez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006, 48:89-96.
102. Chatzikyriakou S.V., Tziakas D.N., Chalikias G.K., et al. Serum levels of collagen type-I degradation markers are associated with vascular stiffness in chronic heart failure patients. Eur J Heart Fail 2008, 10:1181-1185.
103. Smedsrød B., Melkko J., Risteli L., Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 1990, 271:345-350.
104. Melkko J., Hellevik T., Risteli L., Risteli J., Smedsrød B. Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 1994, 179:405-412.
105. McNulty M., Mahmud A., Spiers P., Feely J. Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects. J Hum Hypertens 2006, 20:867-873.
106. Demers L.M., Costa L., Lipton A. Biochemical markers and skeletal metastases. Cancer 2000, 88:2919-2926.
107. Christenson R.H. Biomarkers of bone metabolism: an overview. Clin Biochem 1997, 30:573-593.
108. Grigorescu M. Noninvasive biochemical markers of liver fibrosis. J Gastrointestin Liver Dis 2006, 15:149-159.
109. Urena P., de Vernejoul M.-C. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999, 55:2141-2156.
110. Nakamura R.N. Progress in use of biochemical and biological markers for evaluation of rheumatoid arthritis. J Clin Lab Anal 2000, 14:305-313.
111. Thickett D.R., Poole A.R., Millar A.B. The balance between collagen synthesis and degradation in diffuse lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2001, 18:27-33.
112. Rejnmark L., Buus N.H., Vestergaard P., Andreasen F., Larsen M.L., Mosekilde L. Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest 2002, 32:581-589.